Fenwick represented Amyris, Inc. (NASDAQ: AMRS), the industrial bioscience company, in its offering of $57.6 million aggregate principal amount of the Company’s 9.5% Convertible Senior Notes due 2019. The notes were sold only to qualified institutional buyers and institutional accredited investors in a private placement.

The Fenwick transaction team included corporate partners Daniel Winnike and David Michaels and corporate associates Faisal Rashid, Priscila Bastazin, Ryan McRobert and Seth Popick.

Login

Don’t have an account yet?

Register